![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:4910I Healthcare Enterprise Group PLC 11 February 2005 Healthcare Enterprise Group PLC Increased shareholding in Optiscope Technologies Ltd Development milestones achieved Healthcare Enterprise Group PLC ("HCEG"), the international healthcare products and services company, announces agreement to increase its shareholding in Optiscope Technologies ("Optiscope") to 66.25% for a consideration of $100,000 payable in cash. This follows the achievement of significant development milestones by Optiscope. Optiscope has a range of rigid disposable endoscopes and is one of HCEG's key portfolio technologies. In November 2004, HCEG, Optiscope and Wahl Optoparts, part of Jenoptik AG, entered agreement to finalise the development of Optiscope and bring it to production via a series of pre-agreed milestones leading to the manufacture of a prototype for clinical testing. The initial important performance indicators have been reached resulting in a planned run of 1,000 of these devices to be available in four to six weeks. Optiscope combines a revolutionary, patented optical design with innovative plastic manufacturing methods and components, to produce a commercially viable and fully disposable surgical endoscope. This gives the device a clinical and economic advantage, by removing the risk of cross contamination normally associated with the re-use of expensive re-usable endoscopy equipment. Optiscope has been technically proven to match or better the performance criteria of existing re-usable endoscopes. In addition to the elimination of the cross contamination problem, a key advantage of the Optiscope products are their low cost per unit. A conventional laproscopic endoscope retails for approximately $3,000, a significant capital investment, with cleaning, sterilisation and repair for re-use, at additional cost and a frequent reason for the creation of bottlenecks in clinical procedures. By offering a low cost single use, disposable alternative, Optiscope provides an economically viable solution for budgetary constrained hospitals worldwide. The Optiscope family of products will be made available to hospitals and clinics at an extremely attractive unit cost. Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented: "One of our founding principles is to introduce new products into the international healthcare marketplace which address an immediate economic and social need. Optiscope has huge market potential as it addresses problems common to overstretched hospitals throughout the world - eliminating cross contamination and helping to reduce procedure times. "Optiscope has received modification by Wahl Optoparts and has been bench tested to exacting standards. We look forward to the next step towards commercialisation. "We anticipate more significant positive news relating to Optiscope in the future." 11 February 2005 Enquiries: Healthcare Enterprise Group PLC 020 7351 7500 Stuart Bruck - Executive Chairman Gordon A Wood - COO College Hill Nicholas Nelson/Corinna Dorward 020 7457 2020 Notes to editors Endoscopy An endoscope is a surgical optical instrument for the examination of internal tissues and organs in the body and is an aid to surgical operations. According to research data compiled by HCEG, the world-wide market size for rigid endoscopes is approximately four to five hundred million dollars per annum and growing. The cost of a re-useable rigid endoscope incorporating fibre optics is circa $3,000 per instrument. These are frequently damaged during use, resulting in costly repairs and treatment delays. They also require disinfection, decontamination, sterilization and servicing following each operation and, with a life span of approximately 200 operations, the estimated cost per use is $40. This information is provided by RNS The company news service from the London Stock Exchange END HOLGUUQPPUPAGRU
1 Year Healthcare Enterprise Chart |
1 Month Healthcare Enterprise Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions